| Name | Title | Contact Details |
|---|
Echo Healthcare Acquisition Corp is a Vienna, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Maxim Healthcare Services is a healthcare staffing agency that provides recruitment, training, and management of a diverse healthcare workforce for their clients.
Bringing Together the Heart and Science of Medical Management Genex was founded in 1978 with the same directive it operates under today — helping injured workers return to their jobs in a safe and efficient manner through compassionate case management, thus reducing health care costs and disability expenses for our customers. Our medical and business professionals provide comprehensive care management and multicultural services from locations across the United States and Canada.
Meta Nutrition - The platform that knows what to eat!
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.